Among the largest biopharmaceutical companies, New York-based Pfizer continues to grab headlines on the monumental development of its successful Covid vaccine, now called Comirnaty, with BioNTech.
The Pfizer shares had a strong performance, rising 60.42% in 2021 on the approval and contribution of the Covid vaccines. The stock is down 8.36% year-to-date.
Before purchasing their shares, you should understand the company, its fundamentals, and what investors consider when looking at the stock.
Are Pfizer (PFE) shares appropriate for your portfolio? We will provide you with some of the investing attributes as of January 18, 2022, from Yahoo Finance:
– Market Capitalization: $303.6 Billion – Average Volume: 43,340,212 – Trailing P/E Ratio (TTM): 15.45 – Forward P/E Ratio: 11.07 – 52 Week H/L Range: $33.36-$61.71 – Dividend Yield: 2.96% – Beta: 0.64
Pfizer (PFE) is considered a large-cap stock with a market capitalization of over $300 billion and is included in the S&P 500 index. You can calculate the market capitalization by multiplying its stock price by the number of shares outstanding.
The price-earnings or PE ratio is the current market price divided by the company’s earnings per share or EPS. You can compare the PE multiple to its historical ratio, respective sector, and the S&P 500 market proxy.
Pfizer’s dividend yield is the annual cash dividend paid of $1.60 per share to an investor as a percentage of its current market price, or 2.96%. This yield is above average compared to the S&P 500’s rate.